Okyo Pharma Limited ADR (OKYO)

$2.03 -0.03 (-1.46%)
Market Cap 77.48M
Revenue (ttm) 0.00
Net Income (ttm) -4.71M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 21,400
Avg Vol 154,244
Day's Range N/A - N/A
Shares Out 37.61M
Stochastic %K 67%
Beta -0.06
Analysts Strong Sell
Price Target $6.00

Company Profile

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase II clinical trials for the treatment of dry eye disease; in Phase II clinical trial to treat neuropathic corneal pain; and is in preclinical trial to treat allergic conjunctivitis and uveitis. The company is also developing OK-201 for the treatment acu...

Industry: Biotechnology
Sector: Healthcare
Phone: 44 20 7495 2379
Address:
14/15 Conduit St, Floor 4, London, United Kingdom
InvisibleHandV2
InvisibleHandV2 Dec. 25 at 12:44 PM
$OKYO Capital stewardship is becoming the defining attribute for how this story is priced. Commercial adoption must become steadier to neutralize skepticism around sustainability. Aligned incentives and governance can stabilize expectations. The market will respond to evidence, not speculation.
0 · Reply
Oscarca
Oscarca Dec. 22 at 12:13 PM
$OKYO Great things are coming in 2026 for OKYO 🙏🏼
0 · Reply
Orlandotrader
Orlandotrader Dec. 19 at 1:41 PM
$OKYO Ringing the Bell at the Nasdeq this Am.
0 · Reply
moosegoose
moosegoose Dec. 15 at 2:28 PM
$OKYO 5th sizeable purchase by Gabriele in 3 months now…. Crazy. Times the dips well. He owns close to 30% of the company now. Big move coming up. Get in before we run to $3+ https://www.investing.com/news/company-news/okyo-pharma-executive-chairman-increases-stake-in-company-93CH-4408374
0 · Reply
Stock_Catcher
Stock_Catcher Dec. 15 at 1:31 PM
$OKYO OKYO Pharma Announces Chairman and Founder Acquires Shares
0 · Reply
moosegoose
moosegoose Dec. 12 at 5:28 PM
$OKYO holding strong
1 · Reply
rp6577
rp6577 Dec. 12 at 4:33 PM
$OKYO added
0 · Reply
ppl_first
ppl_first Dec. 12 at 1:04 PM
$OKYO real catalyst is its upcoming larger neuropathic corneal pain trial. A clear readout could reset valuation to where this stock should be, while failure means a trip to the morgue.
1 · Reply
ppl_first
ppl_first Dec. 12 at 1:02 PM
$OKYO OKYO is planning a larger multicenter trial (100 patients) for neuropathic corneal pain, meant to optimize dose for Phase 3 design. That trial is slated to begin in Q1 2026 and topline data are expected during 2026, likely mid to late, not immediate.
0 · Reply
ppl_first
ppl_first Dec. 12 at 12:49 PM
$OKYO The data is interesting, but it’s the scientific equivalent of “looks promising in mice.” Nice support. The market seems to have agreed, bought a little, and went back to doom scrolling because nothing really changed the company’s fate. Sell the news if it’s back to silence for a while.
0 · Reply
Latest News on OKYO
OKYO Pharma to Ring the Opening Bell at Nasdaq

Dec 19, 2025, 7:00 AM EST - 6 days ago

OKYO Pharma to Ring the Opening Bell at Nasdaq

OKYO Pharma Announces Chairman and Founder Acquires Shares

Dec 15, 2025, 8:30 AM EST - 10 days ago

OKYO Pharma Announces Chairman and Founder Acquires Shares

OKYO Pharma to Present at OIS XV in San Diego

Nov 18, 2025, 8:30 AM EST - 5 weeks ago

OKYO Pharma to Present at OIS XV in San Diego

OKYO Pharma Announces Registration Pathway with 100 Patient Multi-Center Clinical Trial of Urcosimod in Neuropathic Corneal Pain

Sep 22, 2025, 8:30 AM EDT - 3 months ago

OKYO Pharma Announces Registration Pathway with 100 Patient Multi-Center Clinical Trial of Urcosimod in Neuropathic Corneal Pain

OKYO Pharma Unveils Strong Phase 2 Clinical Trial Results for Urcosimod to Treat Neuropathic Corneal Pain

Jul 16, 2025, 9:21 AM EDT - 5 months ago

OKYO Pharma Unveils Strong Phase 2 Clinical Trial Results for Urcosimod to Treat Neuropathic Corneal Pain

Goldman Small Cap Research Issues New Research Update on OKYO Pharma Limited

Jun 11, 2025, 10:05 AM EDT - 7 months ago

Goldman Small Cap Research Issues New Research Update on OKYO Pharma Limited

OKYO Pharma to Present at the GPCRs-Targeted Drug Discovery Summit

May 19, 2025, 7:00 AM EDT - 7 months ago

OKYO Pharma to Present at the GPCRs-Targeted Drug Discovery Summit

OKYO Pharma Announces Plans to Accelerate the Clinical Development of Urcosimod to Treat Neuropathic Corneal Pain

Apr 30, 2025, 7:00 AM EDT - 8 months ago

OKYO Pharma Announces Plans to Accelerate the Clinical Development of Urcosimod to Treat Neuropathic Corneal Pain

OKYO Pharma Announces Positive Data in Long-Term Stability of Urcosimod

Mar 31, 2025, 8:00 AM EDT - 9 months ago

OKYO Pharma Announces Positive Data in Long-Term Stability of Urcosimod

OKYO Pharma Announces Chairman and CEO Acquire Shares

Jan 31, 2025, 7:00 AM EST - 11 months ago

OKYO Pharma Announces Chairman and CEO Acquire Shares

Goldman Small Cap Research Publishes New Research Report on OKYO Pharma Limited

Jan 30, 2025, 9:45 AM EST - 11 months ago

Goldman Small Cap Research Publishes New Research Report on OKYO Pharma Limited

MUSQ Global Music Industry ETF and OKYO Pharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Nov 15, 2024, 9:00 AM EST - 1 year ago

MUSQ Global Music Industry ETF and OKYO Pharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

MUSQ

OKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal Pain

Oct 23, 2024, 7:00 AM EDT - 1 year ago

OKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal Pain

OKYO Pharma and SolarMax Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Aug 23, 2024, 9:00 AM EDT - 1 year ago

OKYO Pharma and SolarMax Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

SMXT

OKYO Pharma CEO Interview to Air on Bloomberg TV

Aug 23, 2024, 9:00 AM EDT - 1 year ago

OKYO Pharma CEO Interview to Air on Bloomberg TV

OKYO Pharma Announces Chairman Acquires Shares

Aug 23, 2024, 7:00 AM EDT - 1 year ago

OKYO Pharma Announces Chairman Acquires Shares

OKYO Pharma Participates in H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Aug 15, 2024, 12:13 PM EDT - 1 year ago

OKYO Pharma Participates in H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

OKYO Pharma Granted European Patent Covering OK-101 Chemerin Analogs and Their Method of Use

Aug 6, 2024, 7:00 AM EDT - 1 year ago

OKYO Pharma Granted European Patent Covering OK-101 Chemerin Analogs and Their Method of Use

OKYO Pharma to Initiate Neuropathic Corneal Pain Trial for OK-101

Jul 11, 2024, 7:00 AM EDT - 1 year ago

OKYO Pharma to Initiate Neuropathic Corneal Pain Trial for OK-101

OKYO Pharma Announces Promising Categorical Data from OK-101 Phase 2 Trial in Dry Eye Disease

Jul 10, 2024, 7:00 AM EDT - 1 year ago

OKYO Pharma Announces Promising Categorical Data from OK-101 Phase 2 Trial in Dry Eye Disease

OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at the Dry Horizons Symposium, a Partner Meeting of the Association for Research in Vision and Ophthalmology (ARVO)

Apr 30, 2024, 7:00 AM EDT - 1 year ago

OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at the Dry Horizons Symposium, a Partner Meeting of the Association for Research in Vision and Ophthalmology (ARVO)

OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024

Apr 8, 2024, 7:00 PM EDT - 1 year ago

OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024

OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive Surgery

Apr 2, 2024, 7:00 AM EDT - 1 year ago

OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive Surgery

OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101

Mar 22, 2024, 7:00 AM EDT - 1 year ago

OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101

OKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease Trial

Mar 21, 2024, 7:00 AM EDT - 1 year ago

OKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease Trial

OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader Event

Mar 20, 2024, 7:00 AM EDT - 1 year ago

OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader Event

OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain

Feb 9, 2024, 7:00 AM EST - 2 years ago

OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain

OKYO Pharma to Present at the Biotech Showcase Conference in San Francisco, January 8-10, 2024

Jan 5, 2024, 9:30 AM EST - 2 years ago

OKYO Pharma to Present at the Biotech Showcase Conference in San Francisco, January 8-10, 2024

OKYO Pharma Announces Filing of an Investigational New Drug (IND) Application for OK-101 to Treat Neuropathic Corneal Pain (“NCP”)

Oct 9, 2023, 7:00 AM EDT - 2 years ago

OKYO Pharma Announces Filing of an Investigational New Drug (IND) Application for OK-101 to Treat Neuropathic Corneal Pain (“NCP”)

OKYO Pharma Announces Closing of $4.0 Million Registered Direct Offering of Ordinary Shares

Sep 15, 2023, 7:00 AM EDT - 2 years ago

OKYO Pharma Announces Closing of $4.0 Million Registered Direct Offering of Ordinary Shares

OKYO Pharma Announces Pricing of $4.0 Million Registered Direct Offering of Ordinary Shares

Sep 14, 2023, 9:15 AM EDT - 2 years ago

OKYO Pharma Announces Pricing of $4.0 Million Registered Direct Offering of Ordinary Shares

OKYO Pharma Limited Announces Withdrawal of Public Offering

Sep 14, 2023, 8:45 AM EDT - 2 years ago

OKYO Pharma Limited Announces Withdrawal of Public Offering

OKYO Pharma Announces Public Offering of Ordinary Shares

Sep 13, 2023, 4:05 PM EDT - 2 years ago

OKYO Pharma Announces Public Offering of Ordinary Shares

OKYO Pharma Completes Enrollment in Phase 2 Clinical Trial of OK-101 to treat Dry Eye Disease

Sep 8, 2023, 7:00 AM EDT - 2 years ago

OKYO Pharma Completes Enrollment in Phase 2 Clinical Trial of OK-101 to treat Dry Eye Disease

OKYO Pharma Achieves 90% Enrollment in 240-Patient Phase 2 Clinical Trial of OK-101 to treat Dry Eye Disease (“DED”)

Aug 30, 2023, 7:00 AM EDT - 2 years ago

OKYO Pharma Achieves 90% Enrollment in 240-Patient Phase 2 Clinical Trial of OK-101 to treat Dry Eye Disease (“DED”)

OKYO Pharma Limited Reports Annual Results for the Twelve Months Ended March 31, 2023

Aug 15, 2023, 9:00 AM EDT - 2 years ago

OKYO Pharma Limited Reports Annual Results for the Twelve Months Ended March 31, 2023

OKYO Pharma Announces Proposed Public Offering of Ordinary Shares

Jul 28, 2023, 5:25 PM EDT - 2 years ago

OKYO Pharma Announces Proposed Public Offering of Ordinary Shares

OKYO Pharma Limited Receives Nasdaq Deficiency Notice

Jul 28, 2023, 5:05 PM EDT - 2 years ago

OKYO Pharma Limited Receives Nasdaq Deficiency Notice

OKYO Pharma Plans to Initiate Phase 2 Trial of OK-101 in Neuropathic Corneal Pain (“NCP”) Following Announcement of Clinical Trial Agreement with Tufts Medical Center

Jul 28, 2023, 7:01 AM EDT - 2 years ago

OKYO Pharma Plans to Initiate Phase 2 Trial of OK-101 in Neuropathic Corneal Pain (“NCP”) Following Announcement of Clinical Trial Agreement with Tufts Medical Center

OKYO Pharma Announces Appointment of William A. Clementi as Chief Operating Officer

Jul 27, 2023, 11:30 AM EDT - 2 years ago

OKYO Pharma Announces Appointment of William A. Clementi as Chief Operating Officer

OKYO Pharma Announces Randomized Segment Now Underway in Phase 2 Clinical Trial of Topical Ocular OK-101 for Dry Eye Disease

Jun 6, 2023, 9:30 AM EDT - 2 years ago

OKYO Pharma Announces Randomized Segment Now Underway in Phase 2 Clinical Trial of Topical Ocular OK-101 for Dry Eye Disease

OKYO Pharma Announces Presentations at the American Society of Cataract and Refractive Surgery (ASCRS 2023) in San Diego, CA, May 5-8, 2023

May 3, 2023, 2:00 AM EDT - 2 years ago

OKYO Pharma Announces Presentations at the American Society of Cataract and Refractive Surgery (ASCRS 2023) in San Diego, CA, May 5-8, 2023

OKYO Pharma Announces First-Patient First-Visit for Phase 2 Trial Evaluating Efficacy and Safety of OK-101 in Patients with Dry Eye Disease

May 2, 2023, 2:00 AM EDT - 2 years ago

OKYO Pharma Announces First-Patient First-Visit for Phase 2 Trial Evaluating Efficacy and Safety of OK-101 in Patients with Dry Eye Disease

OKYO Pharma Announces Activation of First Clinical Trial Site in the U.S. for the Phase 2 Trial Evaluating OK-101 for the Treatment of Dry Eye Disease

Apr 25, 2023, 2:00 AM EDT - 2 years ago

OKYO Pharma Announces Activation of First Clinical Trial Site in the U.S. for the Phase 2 Trial Evaluating OK-101 for the Treatment of Dry Eye Disease

OKYO Pharma Management Takes Company Stock In Private Placement Instead Of Deferred Pay

Apr 18, 2023, 10:00 AM EDT - 2 years ago

OKYO Pharma Management Takes Company Stock In Private Placement Instead Of Deferred Pay

Notice of General Meeting and Publication of Circular

Apr 5, 2023, 2:00 AM EDT - 2 years ago

Notice of General Meeting and Publication of Circular

Notice of Intention to Delist From The London Stock Exchange

Apr 4, 2023, 2:00 AM EDT - 2 years ago

Notice of Intention to Delist From The London Stock Exchange

OKYO Pharma Today Announces Director Acquires Shares

Mar 30, 2023, 2:01 AM EDT - 2 years ago

OKYO Pharma Today Announces Director Acquires Shares

OKYO Pharma Announces PDMR Dealing

Mar 24, 2023, 3:00 AM EDT - 2 years ago

OKYO Pharma Announces PDMR Dealing

OKYO Pharma Announces Phase 2 Trial of OK-101 Drug to Treat Dry Eye Disease is now listed on the ClinicalTrials.gov Public Website

Mar 16, 2023, 3:01 AM EDT - 3 years ago

OKYO Pharma Announces Phase 2 Trial of OK-101 Drug to Treat Dry Eye Disease is now listed on the ClinicalTrials.gov Public Website

InvisibleHandV2
InvisibleHandV2 Dec. 25 at 12:44 PM
$OKYO Capital stewardship is becoming the defining attribute for how this story is priced. Commercial adoption must become steadier to neutralize skepticism around sustainability. Aligned incentives and governance can stabilize expectations. The market will respond to evidence, not speculation.
0 · Reply
Oscarca
Oscarca Dec. 22 at 12:13 PM
$OKYO Great things are coming in 2026 for OKYO 🙏🏼
0 · Reply
Orlandotrader
Orlandotrader Dec. 19 at 1:41 PM
$OKYO Ringing the Bell at the Nasdeq this Am.
0 · Reply
moosegoose
moosegoose Dec. 15 at 2:28 PM
$OKYO 5th sizeable purchase by Gabriele in 3 months now…. Crazy. Times the dips well. He owns close to 30% of the company now. Big move coming up. Get in before we run to $3+ https://www.investing.com/news/company-news/okyo-pharma-executive-chairman-increases-stake-in-company-93CH-4408374
0 · Reply
Stock_Catcher
Stock_Catcher Dec. 15 at 1:31 PM
$OKYO OKYO Pharma Announces Chairman and Founder Acquires Shares
0 · Reply
moosegoose
moosegoose Dec. 12 at 5:28 PM
$OKYO holding strong
1 · Reply
rp6577
rp6577 Dec. 12 at 4:33 PM
$OKYO added
0 · Reply
ppl_first
ppl_first Dec. 12 at 1:04 PM
$OKYO real catalyst is its upcoming larger neuropathic corneal pain trial. A clear readout could reset valuation to where this stock should be, while failure means a trip to the morgue.
1 · Reply
ppl_first
ppl_first Dec. 12 at 1:02 PM
$OKYO OKYO is planning a larger multicenter trial (100 patients) for neuropathic corneal pain, meant to optimize dose for Phase 3 design. That trial is slated to begin in Q1 2026 and topline data are expected during 2026, likely mid to late, not immediate.
0 · Reply
ppl_first
ppl_first Dec. 12 at 12:49 PM
$OKYO The data is interesting, but it’s the scientific equivalent of “looks promising in mice.” Nice support. The market seems to have agreed, bought a little, and went back to doom scrolling because nothing really changed the company’s fate. Sell the news if it’s back to silence for a while.
0 · Reply
Orlandotrader
Orlandotrader Dec. 11 at 7:44 PM
$OKYO The Dump
2 · Reply
topstockalerts
topstockalerts Dec. 11 at 4:34 PM
$OKYO setting up nicely.. 🍾
0 · Reply
rp6577
rp6577 Dec. 11 at 4:08 PM
$OKYO the company is just so perfectly placed for a partnership or buyout. Orphan drug designation and they aimed at just reducing pain but it now looks like it actually helps recovery as well. Also don’t forget that there is the DED indications as well $XBI
1 · Reply
Oscarca
Oscarca Dec. 11 at 4:08 PM
$OKYO
0 · Reply
LumiTrader
LumiTrader Dec. 11 at 4:01 PM
Re-entry at 2.30 with stop loss under 2.10. $OKYO
1 · Reply
rp6577
rp6577 Dec. 11 at 4:01 PM
$OKYO great new data
0 · Reply
JohnTrack
JohnTrack Dec. 11 at 3:54 PM
$OKYO new data https://www.rapidticker.com/news/okyo-sec-filing-a81859
0 · Reply
Orlandotrader
Orlandotrader Dec. 11 at 3:11 PM
$OKYO Drug is having a Positive Effect On Corneal Nerve with Structural improvements. Patients treated with 0.05% urcosimod demonstrated directionally favorable improvements in nerve fiber count and fiber length, trends not observed in the placebo group These findings suggest that urcosimod may have a positive impact on corneal nerve health in patients with neuropathic corneal pain.
0 · Reply
prismmarketview
prismmarketview Dec. 11 at 3:10 PM
OKYO Pharma’s (NASDAQ: $OKYO) Urcosimod eye drop is showing more than just pain relief in NCP, with Phase 2 imaging now indicating directional improvements in corneal nerve fiber count and length versus placebo, hinting at potential nerve-regenerative benefits alongside symptom control. https://prismmarketview.com/okyo-pharma-reports-encouraging-corneal-nerve-improvements-in-phase-2-study-for-neuropathic-corneal-pain/
0 · Reply
LumiTrader
LumiTrader Dec. 11 at 1:35 PM
Position fully exited with a positive return. $OKYO
0 · Reply
Mapagotrades
Mapagotrades Dec. 11 at 1:31 PM
$OKYO OKYO Pharma Announces New Data Showing Favorable Corneal Nerve Outcomes in Phase 2 Study for Neuropathic Corneal Pain
0 · Reply
Stock_Catcher
Stock_Catcher Dec. 11 at 1:30 PM
$OKYO OKYO Pharma Announces New Data Showing Favorable Corneal Nerve Outcomes in Phase 2 Study for Neuropathic Corneal Pain
0 · Reply